0
Allergy and Airway |

Role of Omalizumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA)

María del Valle Somiedo Gutiérrez, MD; Carolina Cisneros, PhD; Rosa Girón Moreno, PhD; Gilda Fernandes Vasconcelos, MD; Gonzalo Segrelles, PhD; Silvia Sanchez, PhD
Author and Funding Information

Hospital Universitario de La Princesa, Madrid, Spain


Chest. 2014;145(3_MeetingAbstracts):19A. doi:10.1378/chest.1799420
Text Size: A A A
Published online

Abstract

SESSION TITLE: Asthma

SESSION TYPE: Slide Presentations

PRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PM

PURPOSE: Several studies have shown that there is significant clinical improvement, better control of symptoms and reduce of oral corticosteroids and itraconazol, in patients with ABPA treated with omalizumab. The aim of the study was to determine the effect of omalizumab treatment on clinical efficacy in 6 ABPA patients.

METHODS: We followed 6 cases with ABPA treated with omalizumab. Oral and inhaled corticosteroid and itraconazol doses previous and during omalizumab treatment, indication of treatment, spirometric evolution, clinical improvement and side effects, were analyzed.

RESULTS: 6 patients (3 asthma and 3 cystic fibrosis) were recluted. The mean age was 40,67 years. The main purpose of treatment was reducing side effects of maintenance oral corticosteroids therapy in 3 patients, poor clinical control despite optimal treatment in 2 patients and worsening of immunodeficiency due to oral corticosteroids in 1 HIV patient. The mean treatment period was 18 months (±4). The mean prednisone dose was 19 mg daily (±6). Oral corticosteroids were discontinued in 5 patients. Mean BDP equivalent was 1550 µg (±843). 5 patients were treated with itraconazol and it was stopped in all of them. Spirometry was performed in 5 patients: initial mean FEV1% was 58,4 and after 12 months mean FEV1% was 79. ACT values improvement were observed. GETE rating was excellent in 3, good in 2 and moderate in 1 patient. 2 of them developed local erythema.

CONCLUSIONS: In this case series study, all patients had positive clinical response to therapy with omalizumab, showing a good safety profile. Oral corticosteroids and itraconazol were discontinued in the majority of them.

CLINICAL IMPLICATIONS: Although Omalizumab treatment is not already indicated, there are some reports about successful response to Omalizumab in cystic fibrosis or asthma complicated with ABPA. According to this case series study, as well as in previous reports, the use of Omalizumab to control ABPA in steroid dependent patients is recommended. Further studies are needed to define its therapeutical role.

DISCLOSURE: The following authors have nothing to disclose: María del Valle Somiedo Gutiérrez, Carolina Cisneros, Rosa Girón Moreno, Gilda Fernandes Vasconcelos, Gonzalo Segrelles, Silvia Sanchez

Omalizumab treatment is not already indicated but there are some reports about successful response to Omalizumab in cystic fibrosis or asthma complicated with ABPA.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Novel targets of omalizumab in asthma. Curr Opin Pulm Med Published online Oct 31, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543